BRCA1 and triple-negative breast carcinoma: To achieve this, we generated talazoparib (BMN673)-resistant cell lines (designated as BR#01 to BR#31) from the initially sensitive BRCA1-mutated triple-negative breast cancer (TNBC) cell line SUM149 by exposing them chronically to gradually increasing concentrations of talazoparib (Figure 1A and Supplemental Figure 1A; supplemental material available online with this article; https://doi.org/10.1172/JCI173757DS1).